Exenatide

What it is

Exenatide is a synthetic copy of exendin-4, a 39-amino-acid peptide isolated from the saliva of the Gila monster, a venomous lizard of the American Southwest. Exendin-4 shares about half its sequence with human GLP-1 and activates the same receptor, but it resists the enzyme DPP-4 that destroys natural GLP-1 within minutes, giving it a useful duration of action. Byetta reached the market in 2005 as the first GLP-1 receptor agonist. ²

Two formulations were sold: Byetta, a twice-daily formulation, and Bydureon, a microsphere formulation that releases exenatide over a week. The most recent label is for Bydureon BCise, the autoinjector version. AstraZeneca discontinued both in the US in 2024 as semaglutide, dulaglutide and tirzepatide took over the market. ¹³

How it works

Exenatide activates GLP-1 receptors on pancreatic beta cells, increasing insulin release when glucose is high, suppressing glucagon, slowing stomach emptying and reducing appetite through receptors in the brainstem and hypothalamus. The twice-daily form mainly blunts the post-meal glucose rise through gastric slowing; the weekly form produces steadier receptor activation and larger effects on fasting glucose. The appetite effect is real but weaker than with later agonists. ¹²

What human research shows

The label summarizes the registration trials: added to metformin, a sulfonylurea or both, weekly exenatide lowered HbA1c by roughly 1.3 to 1.9 percentage points over 24 to 30 weeks, with weight losses of 2 to 3 kg. In head-to-head trials against liraglutide and against insulin glargine it was less effective or similar on HbA1c. ¹

EXSCEL randomized 14,752 patients with type 2 diabetes, most with cardiovascular disease, to weekly exenatide or placebo and followed them for a median of 3.2 years. Major cardiovascular events occurred in 11.4% of exenatide patients and 12.2% of placebo patients, a hazard ratio of 0.91 that met the noninferiority (safety) criterion but narrowly missed statistical superiority. All-cause mortality was lower on exenatide in a secondary analysis. ⁸

The comparison that matters for the online market is weight. In dedicated obesity trials, liraglutide produced about 8% weight loss over 56 weeks, semaglutide about 15% over 68 weeks and tirzepatide up to 22.5% over 72 weeks, versus 2 to 3% with placebo. Exenatide never had an obesity trial and its diabetes-trial weight losses were in the 2 to 3 kg range. ⁴⁵⁶⁷

Safety

Nausea is the most common adverse effect, affecting a large minority of patients early in treatment, with vomiting and diarrhea less often. The weekly formulation causes injection-site nodules in many patients because of the microsphere carrier. The label carries a boxed warning for thyroid C-cell tumors seen in rodents, and warnings for pancreatitis, kidney injury from dehydration, hypoglycemia with sulfonylureas or insulin, and hypersensitivity. Exenatide is cleared by the kidney and is not recommended in severe kidney disease. EXSCEL found no excess of pancreatitis, pancreatic cancer or medullary thyroid cancer over three years. ¹⁸